Merck agrees to let other drug makers make its COVID pill

Pharmaceutical company Merck has agreed to enable other drug makers worldwide to make its COVID-19 therapy, the primary pill that has been proven to be efficient in opposition to the illness

The Medicines Patent Pool stated in an announcement that it had signed a voluntary licensing settlement for molnupiravir with Merck and its associate Ridgeback Biotherapeutics.

The settlement will enable the Medicines Patent Pool to grant additional licenses to certified firms who’re authorized to make the drug. Neither drug maker will obtain royalties beneath the settlement for so long as the World Health Organization deems COVID-19 to be international emergency. Molnupiravir is the primary pill that has been proven to deal with the illness.

Charles Gore, the chief director of the Medicines Patent Pool, stated the early outcomes for molnupiravir had been “compelling” and that he hoped this primary voluntary licensing settlement for a COVID-19 therapy would lead to others.

Despite repeated requests from governments and well being officers, no vaccine makers have agreed to an analogous deal. A hub arrange by WHO in South Africa supposed to share messenger RNA vaccine recipes and applied sciences has not enticed a single pharmaceutical to be part of.

Merck has requested its pill be licensed by each the U.S. Food and Drug Administration and the European Medicines Agency, choices that would come inside weeks.

Merck reported this month that molnupiravir minimize hospitalizations and deaths by half amongst sufferers with early signs of COVID-19. The outcomes had been so sturdy that impartial medical consultants monitoring the trial really useful stopping it early.

It would additionally bolster a two-pronged strategy to the pandemic: therapy by the use of medicine and prevention, primarily via vaccinations.


Follow AP’s pandemic protection at

Back to top button